secwatch.observer — SEC 8-K summary
======================================

Issuer:     MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK:        0001157601
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001628280-26-030896
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Madrigal Q1 Rezdiffra net sales $311.3M (+127% YoY); pipeline expanded with siRNA deal
--------------------------------------------------------------------------------

- Q1 2026 Rezdiffra net sales $311.3M, up 127% YoY from $137.3M; over 42,250 patients on therapy, 2.5x vs Q1 2025.
- Licensed ARO-PNPLA3 from Arrowhead; clinical-stage siRNA targeting PNPLA3 mutation in MASH (≈30% of F2/F3 patients).
- Net loss $94.4M ($3.25/share) vs $73.2M ($2.61) prior year; includes $54.3M one-time upfront BD expenses.
- Cash $817.9M at Mar 31 (down from $988.6M Dec 31); MGL-2086 Phase 1 on track for Q2 2026.
- Operating expenses $404.1M (incl $34M stock comp) vs $216.6M; SG&A up due to commercial investment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157601/000162828026030896/0001628280-26-030896-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157601/000162828026030896/mdgl-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-030896

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer